Stocks Overview

LAST PRICE
0.8899
TODAY'S CHANGE (%)
Trending Down-0.0802 (-8.2672%)

Bid / Lots
0.8851/ 5
Ask / Lots
0.8900/ 30
Open / Previous Close
0.9600 / 0.9701
Day Range
Low 0.8312
High 0.9681
52 Week Range
Low 0.8312
High 6.0000
Volume
3,332,016
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 0.9701
Time	Volume	TPST
09:32 ET	111648	0.93
09:33 ET	307638	0.8895
09:35 ET	23773	0.908
09:37 ET	76498	0.8825
09:39 ET	79581	0.8999
09:42 ET	55937	0.8954
09:44 ET	71814	0.9389
09:46 ET	19303	0.894603
09:48 ET	142637	0.8976
09:50 ET	48157	0.8688
09:51 ET	91919	0.8619
09:53 ET	56747	0.87026
09:55 ET	10920	0.863349
09:57 ET	93107	0.8907
10:00 ET	28337	0.860325
10:02 ET	127150	0.8563
10:04 ET	78461	0.8477
10:06 ET	109036	0.859999
10:08 ET	25713	0.865
10:09 ET	18852	0.863867
10:11 ET	14411	0.8638
10:13 ET	11126	0.8782
10:15 ET	31519	0.8799
10:18 ET	36443	0.8639
10:20 ET	20336	0.86699
10:22 ET	39353	0.87684
10:24 ET	32891	0.8718
10:26 ET	8219	0.873
10:27 ET	61117	0.8814
10:29 ET	32395	0.8898
10:31 ET	35400	0.9
10:33 ET	65334	0.9154
10:36 ET	51987	0.9044
10:38 ET	36903	0.9024
10:40 ET	13196	0.8976
10:42 ET	9569	0.9049
10:44 ET	22770	0.8987
10:45 ET	3794	0.9099
10:47 ET	10344	0.9075
10:49 ET	8263	0.9028
10:51 ET	16596	0.886
10:54 ET	1600	0.8996
10:56 ET	9594	0.8999
10:58 ET	4500	0.8985
11:00 ET	500	0.8973
11:02 ET	3754	0.8974
11:03 ET	900	0.8902
11:05 ET	4440	0.885
11:07 ET	370	0.8847
11:09 ET	3906	0.8848
11:12 ET	2104	0.8848
11:14 ET	3900	0.8853
11:16 ET	200	0.886
11:18 ET	2865	0.8861
11:20 ET	1400	0.88545
11:21 ET	74164	0.8704
11:23 ET	7200	0.8792
11:25 ET	2400	0.8792
11:27 ET	28830	0.8807
11:30 ET	800	0.8807
11:32 ET	10413	0.88689
11:34 ET	2000	0.886
11:36 ET	2544	0.8856
11:38 ET	64113	0.8652
11:39 ET	19334	0.8705
11:41 ET	14015	0.8653
11:43 ET	18554	0.8687
11:45 ET	4399	0.87
11:48 ET	4655	0.8848
11:50 ET	4100	0.883
11:52 ET	5520	0.88
11:54 ET	10600	0.8787
11:56 ET	1013	0.8767
11:57 ET	4215	0.87115
11:59 ET	2500	0.8725
12:01 ET	6191	0.87
12:03 ET	3801	0.8712
12:06 ET	21600	0.875
12:08 ET	200	0.8829
12:10 ET	20231	0.8679
12:12 ET	16990	0.8688
12:14 ET	16200	0.8688
12:15 ET	3400	0.868246
12:17 ET	9500	0.8636
12:19 ET	2400	0.863
12:21 ET	1450	0.861501
12:24 ET	300	0.863
12:26 ET	1100	0.8604
12:28 ET	2801	0.8604
12:30 ET	21964	0.8659
12:32 ET	884	0.8811
12:33 ET	29887	0.8716
12:35 ET	4851	0.8639
12:37 ET	100	0.8639
12:39 ET	7650	0.8626
12:42 ET	900	0.868759
12:44 ET	2242	0.863
12:46 ET	4126	0.865949
12:48 ET	14131	0.8645
12:50 ET	300	0.8698
12:51 ET	4902	0.862018
12:53 ET	1700	0.862
12:55 ET	4308	0.8621
12:57 ET	11029	0.862
01:00 ET	45304	0.8636
01:02 ET	2688	0.865451
01:04 ET	1520	0.868
01:06 ET	779	0.8699
01:08 ET	1518	0.87
01:09 ET	1750	0.8686
01:11 ET	1603	0.8699
01:13 ET	1410	0.8699
01:15 ET	2800	0.8655
01:18 ET	216	0.862
01:20 ET	100	0.868
01:22 ET	200	0.862
01:24 ET	1805	0.8679
01:26 ET	3168	0.8638
01:27 ET	3946	0.8639
01:29 ET	10248	0.86585
01:31 ET	16548	0.8697
01:33 ET	169	0.8698
01:36 ET	250	0.8699
01:38 ET	1690	0.87
01:40 ET	395	0.87
01:42 ET	885	0.8697
01:44 ET	3917	0.8697
01:45 ET	700	0.869435
01:47 ET	1170	0.869
01:49 ET	7661	0.8692
01:54 ET	200	0.8693
01:56 ET	4092	0.8693
01:58 ET	300	0.8692
02:00 ET	13200	0.8691
02:02 ET	261	0.8692
02:03 ET	300	0.8691
02:05 ET	1826	0.8692
02:07 ET	1900	0.8692
02:09 ET	100	0.8692
02:12 ET	350	0.8691
02:14 ET	755	0.8691
02:16 ET	8729	0.8691
02:18 ET	412	0.8699
02:21 ET	2569	0.8696
02:23 ET	2587	0.87
02:25 ET	4000	0.87
02:27 ET	4100	0.87
02:30 ET	703	0.87
02:32 ET	49525	0.8635
02:34 ET	286	0.874
02:36 ET	44215	0.88
02:38 ET	434	0.88
02:39 ET	2200	0.88
02:41 ET	1000	0.8799
02:43 ET	518	0.8796
02:45 ET	1100	0.878204
03:15 ET	1185	0.89
03:17 ET	1995	0.89
03:19 ET	4910	0.8901
03:21 ET	9332	0.8901
03:24 ET	54211	0.89005
03:26 ET	30331	0.896
03:28 ET	18437	0.892204
03:30 ET	18083	0.896
03:32 ET	3824	0.896
03:33 ET	1100	0.8936
03:35 ET	6620	0.8958
03:37 ET	7218	0.8957
03:39 ET	8236	0.8937
03:42 ET	1629	0.8916
03:44 ET	1070	0.8912
03:48 ET	1525	0.8914
03:50 ET	3361	0.8914
03:51 ET	2591	0.8915
03:53 ET	9276	0.8909
03:55 ET	12822	0.891
03:57 ET	15204	0.88605
04:00 ET	15882	0.8899

Data delayed at least 15 minutes.

Nov 13, 2024
- DJ Tempest Therapeutics Is Maintained at Overweight by Piper Sandler, from 12:00PM ET on Wednesday Nov 13, 2024 by Dow Jones
  12:00PM ET on Wednesday Nov 13, 2024 by Dow Jones
- DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co., from 7:35AM ET on Wednesday Nov 13, 2024 by Dow Jones
  7:35AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
- Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:21PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:21PM ET on Tuesday Nov 12, 2024 by Dow Jones
- Press Release: Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:21PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:21PM ET on Tuesday Nov 12, 2024 by Dow Jones
- Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesTPST Tempest Therapeutics Inc	24.5M	-0.6x	---
United StatesGOVX GeoVax Labs Inc	24.6M	-0.2x	---
United StatesAEON Aeon Biopharma Inc	24.2M	-0.1x	---
United StatesCLCS Cell Source Inc	24.7M	-4.0x	---
United StatesOCEA Ocean Biomedical Inc	24.9M	-0.2x	---
United StatesNRSN Neurosense Therapeutics Ltd	25.3M	-2.8x	---
As of 2024-11-15

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

Contact Information

Headquarters: 2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE, CA, United States 94005
Phone: 415-798-8589
Fax: 302-655-5049

Executives

Independent Chairman of the Board: Michael Raab
President, Chief Executive Officer, Director: Stephen Brady
Executive Vice President, Chief Medical Officer: Samuel Whiting
Vice President - Strategy and Finance, Corporate Secretary: Nicholas Maestas
Vice President - Regulatory Affairs: Sheldon Mullins

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$24.5M
Revenue (TTM)	$0.00
Shares Outstanding	25.2M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	-1.76
EPS	$-1.57
Book Value	$1.21
P/E Ratio	-0.6x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Tempest Therapeutics Inc
NASDAQ:TPSTUnited States

Search Criteria

Charts

Recent News

Nov 13, 2024

DJ Tempest Therapeutics Is Maintained at Overweight by Piper Sandler, from 12:00PM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co., from 7:35AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:21PM ET on Tuesday Nov 12, 2024 by Dow Jones

Press Release: Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:21PM ET on Tuesday Nov 12, 2024 by Dow Jones

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar